Minimal sex-differential modulation of reactivity to pathogens and toll-like receptor ligands following infant Bacillus Calmette-Guérin Russia vaccination

Fatoumatta Darboe, Jane U. Adetifa, John Reynolds, Safayet Hossin, Magdalena Plebanski, Mihai G. Netea, Sarah L. Rowland-Jones, Jayne S. Sutherland, Katie L. Flanagan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, has been shown to provide heterologous protection against unrelated pathogens and enhance antibody responses to several routine expanded program on immunization (EPI) vaccines. Understanding these heterologous effects is important for the development of optimal vaccination strategies. We set out to assess the effect of vaccination with BCG Russia of 6-week-old infants on in vitro reactivity to a panel of toll-like receptor (TLR) agonists (TLR2, 4, and 7/8) and heat-killed pathogens [Streptococcus pneumoniae, Candida albicans (CA), and Escherichia coli], and antibody responses to other EPI vaccines compared to BCG naïve infants. We observed no effect of BCG vaccination on innate (TNF-α) or Th2 (IL-4) cytokine responses, but found enhanced CA-specific CD8+IFN-γ+ responses in BCG vaccinated males and females 1 week after vaccination and decreased IFN-γ:IL4 ratio to SP in females. By 12 weeks (but not 1 week) of post-vaccination, there was significant downmodulation of Th1 cytokine responses in BCG vaccinated infants; and TLR-stimulated IL-10 and IL-17 responses declined in BCG vaccinated females but not males. Significant changes also occurred in the BCG naïve group, mainly at 18 weeks, including decreased Th1 and increased IL-10 responses. The effects at 18 weeks were most likely a result of immune modulation by the intervening EPI vaccines given at 8, 12, and 16 weeks of age. There was no effect of BCG vaccination on EPI antibody levels at either time point. Taken together, our results support minimal early heterologous immune modulation by BCG Russia vaccination that did not persist 12 weeks after vaccination.

Original languageEnglish
Article number1092
JournalFrontiers in Immunology
Volume8
Issue numberSEP
DOIs
Publication statusPublished - 8 Sep 2017

Keywords

  • Adaptive immunity
  • Cytokines
  • Heterologous effects
  • Innate immunity
  • Non-specific effects
  • Toll-like receptors
  • Vaccine

Cite this

@article{5fd418d6710646968e7f9f13f5defb8c,
title = "Minimal sex-differential modulation of reactivity to pathogens and toll-like receptor ligands following infant Bacillus Calmette-Gu{\'e}rin Russia vaccination",
abstract = "Bacillus Calmette-Gu{\'e}rin (BCG), the only licensed vaccine against tuberculosis, has been shown to provide heterologous protection against unrelated pathogens and enhance antibody responses to several routine expanded program on immunization (EPI) vaccines. Understanding these heterologous effects is important for the development of optimal vaccination strategies. We set out to assess the effect of vaccination with BCG Russia of 6-week-old infants on in vitro reactivity to a panel of toll-like receptor (TLR) agonists (TLR2, 4, and 7/8) and heat-killed pathogens [Streptococcus pneumoniae, Candida albicans (CA), and Escherichia coli], and antibody responses to other EPI vaccines compared to BCG na{\"i}ve infants. We observed no effect of BCG vaccination on innate (TNF-α) or Th2 (IL-4) cytokine responses, but found enhanced CA-specific CD8+IFN-γ+ responses in BCG vaccinated males and females 1 week after vaccination and decreased IFN-γ:IL4 ratio to SP in females. By 12 weeks (but not 1 week) of post-vaccination, there was significant downmodulation of Th1 cytokine responses in BCG vaccinated infants; and TLR-stimulated IL-10 and IL-17 responses declined in BCG vaccinated females but not males. Significant changes also occurred in the BCG na{\"i}ve group, mainly at 18 weeks, including decreased Th1 and increased IL-10 responses. The effects at 18 weeks were most likely a result of immune modulation by the intervening EPI vaccines given at 8, 12, and 16 weeks of age. There was no effect of BCG vaccination on EPI antibody levels at either time point. Taken together, our results support minimal early heterologous immune modulation by BCG Russia vaccination that did not persist 12 weeks after vaccination.",
keywords = "Adaptive immunity, Cytokines, Heterologous effects, Innate immunity, Non-specific effects, Toll-like receptors, Vaccine",
author = "Fatoumatta Darboe and Adetifa, {Jane U.} and John Reynolds and Safayet Hossin and Magdalena Plebanski and Netea, {Mihai G.} and Rowland-Jones, {Sarah L.} and Sutherland, {Jayne S.} and Flanagan, {Katie L.}",
year = "2017",
month = "9",
day = "8",
doi = "10.3389/fimmu.2017.01092",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",
number = "SEP",

}

Minimal sex-differential modulation of reactivity to pathogens and toll-like receptor ligands following infant Bacillus Calmette-Guérin Russia vaccination. / Darboe, Fatoumatta; Adetifa, Jane U.; Reynolds, John; Hossin, Safayet; Plebanski, Magdalena; Netea, Mihai G.; Rowland-Jones, Sarah L.; Sutherland, Jayne S.; Flanagan, Katie L.

In: Frontiers in Immunology, Vol. 8, No. SEP, 1092, 08.09.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Minimal sex-differential modulation of reactivity to pathogens and toll-like receptor ligands following infant Bacillus Calmette-Guérin Russia vaccination

AU - Darboe, Fatoumatta

AU - Adetifa, Jane U.

AU - Reynolds, John

AU - Hossin, Safayet

AU - Plebanski, Magdalena

AU - Netea, Mihai G.

AU - Rowland-Jones, Sarah L.

AU - Sutherland, Jayne S.

AU - Flanagan, Katie L.

PY - 2017/9/8

Y1 - 2017/9/8

N2 - Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, has been shown to provide heterologous protection against unrelated pathogens and enhance antibody responses to several routine expanded program on immunization (EPI) vaccines. Understanding these heterologous effects is important for the development of optimal vaccination strategies. We set out to assess the effect of vaccination with BCG Russia of 6-week-old infants on in vitro reactivity to a panel of toll-like receptor (TLR) agonists (TLR2, 4, and 7/8) and heat-killed pathogens [Streptococcus pneumoniae, Candida albicans (CA), and Escherichia coli], and antibody responses to other EPI vaccines compared to BCG naïve infants. We observed no effect of BCG vaccination on innate (TNF-α) or Th2 (IL-4) cytokine responses, but found enhanced CA-specific CD8+IFN-γ+ responses in BCG vaccinated males and females 1 week after vaccination and decreased IFN-γ:IL4 ratio to SP in females. By 12 weeks (but not 1 week) of post-vaccination, there was significant downmodulation of Th1 cytokine responses in BCG vaccinated infants; and TLR-stimulated IL-10 and IL-17 responses declined in BCG vaccinated females but not males. Significant changes also occurred in the BCG naïve group, mainly at 18 weeks, including decreased Th1 and increased IL-10 responses. The effects at 18 weeks were most likely a result of immune modulation by the intervening EPI vaccines given at 8, 12, and 16 weeks of age. There was no effect of BCG vaccination on EPI antibody levels at either time point. Taken together, our results support minimal early heterologous immune modulation by BCG Russia vaccination that did not persist 12 weeks after vaccination.

AB - Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, has been shown to provide heterologous protection against unrelated pathogens and enhance antibody responses to several routine expanded program on immunization (EPI) vaccines. Understanding these heterologous effects is important for the development of optimal vaccination strategies. We set out to assess the effect of vaccination with BCG Russia of 6-week-old infants on in vitro reactivity to a panel of toll-like receptor (TLR) agonists (TLR2, 4, and 7/8) and heat-killed pathogens [Streptococcus pneumoniae, Candida albicans (CA), and Escherichia coli], and antibody responses to other EPI vaccines compared to BCG naïve infants. We observed no effect of BCG vaccination on innate (TNF-α) or Th2 (IL-4) cytokine responses, but found enhanced CA-specific CD8+IFN-γ+ responses in BCG vaccinated males and females 1 week after vaccination and decreased IFN-γ:IL4 ratio to SP in females. By 12 weeks (but not 1 week) of post-vaccination, there was significant downmodulation of Th1 cytokine responses in BCG vaccinated infants; and TLR-stimulated IL-10 and IL-17 responses declined in BCG vaccinated females but not males. Significant changes also occurred in the BCG naïve group, mainly at 18 weeks, including decreased Th1 and increased IL-10 responses. The effects at 18 weeks were most likely a result of immune modulation by the intervening EPI vaccines given at 8, 12, and 16 weeks of age. There was no effect of BCG vaccination on EPI antibody levels at either time point. Taken together, our results support minimal early heterologous immune modulation by BCG Russia vaccination that did not persist 12 weeks after vaccination.

KW - Adaptive immunity

KW - Cytokines

KW - Heterologous effects

KW - Innate immunity

KW - Non-specific effects

KW - Toll-like receptors

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85029231793&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01092

DO - 10.3389/fimmu.2017.01092

M3 - Article

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - SEP

M1 - 1092

ER -